Recent investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing significant effects in treating excess mass and diabetes 2 condition. Preclinical information suggest a novel mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/